Deal Watch: Bristol Doubles Down On Five Prime, Roche Continues Diversifying
Executive Summary
Roche buyout of California biotech Adheron will strengthen its pipeline in rheumatoid arthritis and fibrosis. Lilly keeps busy, expanding an immuno-oncology collaboration with China's Innovent and acquiring a Phase III intranasal hypoglycemia candidate from Locemia.